Children with pulmonary arterial hypertension (PAH) report poorer health-related quality of life (HRQoL) than their peers, a study shows. Results...
Claritas Pharmaceuticals now has exclusive worldwide rights to develop and market R-107 — a liquid form of nitric oxide —...
PhaseBio Pharmaceuticals has voluntarily ended the Phase 2b trial testing its investigational pulmonary arterial hypertension (PAH) therapy pemziviptadil (PB1046), due...
The use of the INOpulse combination drug-device therapy demonstrated a clinically meaningful reduction in pulmonary vascular resistance (PVR) — a...
Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib,...
Like many people, I have always treasured the holidays. The weeks between Thanksgiving and New Year’s feel like a time...
“Seeing is believing, but sometimes the most real things in the world are the things we can’t see.” ― Chris...
Aerami Therapeutics, a biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases — including pulmonary arterial hypertension (PAH)...
It turns out that National Cat Herders Day is an occasion people celebrate. Observed on Dec. 15, it’s a day...
For the first few years after I was diagnosed with pulmonary hypertension (PH) in 2017, I always felt an ongoing...
Parents of children with pulmonary hypertension (PH) commonly express concern about the emotional and developmental effects on their healthy offspring....
The presence of specific patterns called centrilobular ground-glass opacifications (cGGOs) in high-resolution computed tomography (HRCT) lung scans is associated with...